FIG 2.

Kaplan-Meier survival curves for 60-day mortality of patients with no COVID-19-associated pulmonary aspergillosis (CAPA) or possible or probable CAPA according to European Confederation for Medical Mycology and International Society for Human and Animal Mycology (ECMM/ISHAM) consensus criteria (log rank test, P = 0.06) (A) and with 0, 1 or 2, and ≥3 positive mycological criteria (B) (log rank test, P = 0.008). The following were considered Aspergillus criteria: from respiratory specimens: (i) direct respiratory sample examination with branched hyphae suggestive of Aspergillus-type hyphae, (ii) respiratory sample culture growing Aspergillus sp., (iii) galactomannan in bronchoalveolar lavage (index of >1.0), and (iv) Aspergillus qPCR in respiratory sample with quantitative cycle (Cq) of <36; and from serum (i) galactomannan in blood (index of >0.5), (ii) positive Aspergillus qPCR in blood with Cq of <40, and (iii) blood BDG of >80 pg/mL.